Polysomnography with quantitative EEG in patients with and without fibromyalgia

Author(s): Rosenfeld VW, Rutledge DN, Stern JM


Purpose:Characterize the polysomnographic (PSG) and quantitative EEG (qEEG) features of fibromyalgia and determine whether fibromyalgia patients differ in these measures when compared with a control sleep disorder population.

Methods:All undergoing all-night PSG for evaluation of a sleep disorder were evaluated for fibromyalgia. The PSGs were interpreted for routine sleep measures, and qEEG was performed to measure the delta and alpha frequency power during non-rapid eye movement sleep. Measures and qEEG were analyzed according to fibromyalgia diagnosis.

Setting:Community-based sleep medicine center.

Patients:All patients undergoing PSG over a 2-year period.


Results:Of the 385 patients in the study population, 133 had fibromyalgia according to American College of Rheumatology criteria. The population's average Epworth Sleepiness Score was 10.5, the average sleep efficiency was 78%, and the Periodic Limb Movement disorder prevalence was 15%. None of these sleep measures differed significantly between the fibromyalgia and non-fibromyalgia groups. Obstructive sleep apnea was present in 45% of the fibromyalgia group. Significant differences were present in the qEEG ratio of delta to alpha frequency power, which was 95% specific for fibromyalgia when ≤1. A qEEG ratio ≤10.5 was 85% sensitive for fibromyalgia, and a qEEG ratio >10.5 had an 89% negative predictive value for fibromyalgia. Among patients with fibromyalgia who were not taking a benzodiazepine or benzodiazepine agonist, a qEEG ratio ≤10.5 was 84% specific and had a 78% positive predictive value.

Conclusions:Sleep disorders identified by routine PSG, including obstructive sleep apnea, are common in fibromyalgia, but periodic leg movement disorder and poor sleep efficiency are not. A qEEG low delta/alpha ratio during non-rapid eye movement sleep can differentiate patients with fibromyalgia from others who are referred for PSG. Consideration of benzodiazepine and benzodiazepine agonist use is important when interpreting the delta/alpha ratio.

Similar Articles

Safety of intravenous immunoglobulin (IVIG) therapy

Author(s): Katz U, Achiron A, Sherer Y, Shoenfeld Y

Intravenous immunoglobulin: adverse effects and safe administration

Author(s): Orbach H, Katz U, Sherer Y, Shoenfeld Y

Complications of intravenous immune globulin treatment in neurologic disease

Author(s): Brannagan TH 3rd, Nagle KJ, Lange DJ, Rowland LP

Adverse effect of polyvalent immunoglobulin in the treatment of Guillain-Barre syndrome

Author(s): Chamouni P, Tamion F, Gueit I, Girault C, Lenain P, et al.

Patient demographics and health plan paid costs in chronic inflammatory demyelinating polyneuropathy

Author(s): Guptill JT, Bromberg MB, Zhu L, Sharma BK, Thompson AR, et al.

Diffuse muscular coactivation [DMC] as a potential source of pain in fibromyalgia -- part 1

Author(s): Donaldson CC, Snelling LS, MacInnis AL, Sella GE, Mueller HH

Pregabalin for fibromyalgia: some relief but no cure

Author(s): Kim L, Lipton S, Deodhar A

The effects of pregabalin on sleep disturbance symptoms among individuals with fibromyalgia syndrome

Author(s): Russell IJ, Crofford LJ, Leon T, Cappelleri JC, Bushmakin AG, et al.

The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia

Author(s): Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, et al.

Prevalence and factors associated with fibromyalgia in Mexican patients with systemic lupus erythematosus

Author(s): Valencia-Flores M, Cardiel MH, Santiago V, Resendiz M, Castaño VA, et al.

The prevalence and characteristics of fibromyalgia in the general population

Author(s): Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L

Estimates of the prevalence of arthritis and other rheumatic conditions in the United States

Author(s): Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, et al.

Prevalence of fibromyalgia in children: a clinical study of Mexican children

Author(s): Clark P, Burgos-Vargas R, Medina-Palma C, Lavielle P, Marina FF

Management of fibromyalgia syndrome

Author(s): Goldenberg DL, Burckhardt C, Crofford L

Fibromyalgia syndrome module at OMERACT 9: domain construct

Author(s): Mease P, Arnold LM, Choy EH, Clauw DJ, Crofford LJ, et al.

Toward development of a fibromyalgia responder index and disease activity score: OMERACT module update

Author(s): Mease PJ, Clauw DJ, Christensen R, Crofford LJ, Gendreau RM, et al.

Nerve ultrasound score in distinguishing chronic from acute inflammatory demyelinating polyneuropathy

Author(s): Kerasnoudis A, Pitarokoili K, Behrendt V, Gold R, Yoon MS

Clinical spectrum of chronic acquired demyelinating polyneuropathies

Author(s): Saperstein DS, Katz JS, Amato AA, Barohn RJ

Chronic inflammatory demyelinating polyradiculoneuropathy

Author(s): Barohn RJ, Kissel JT, Warmolts JR, Mendell JR

Chronic inflammatory polyradiculoneuropathy

Author(s): Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, et al.

Derivation and validation of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy

Author(s): Koski CL, Baumgarten M, Magder LS, Barohn RJ, Goldstein J, et al.

IVIG regulates BAFF expression in patients with chronic inflammatory demyelinating polyneuropathy (CIDP)

Author(s): Ritter C, Förster D, Albrecht P, Hartung HP, Kieseier BC, et al.

Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy

Author(s): Cocito D, Grimaldi S, Paolasso I, Falcone Y, Antonini G, et al.

High prevalence of restless legs syndrome among patients with fibromyalgia: a controlled cross-sectional study

Author(s): Viola-Saltzman M, Watson NF, Bogart A, Goldberg J, Buchwald D